China National Medicines Corporation Ltd. (SHA: 600511)
China
· Delayed Price · Currency is CNY
36.55
+2.16 (6.28%)
Nov 20, 2024, 3:00 PM CST
China National Medicines Corporation Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 51,091 | 49,592 | 45,436 | 46,442 | 40,336 | 44,551 | Upgrade
|
Other Revenue | 103.99 | 103.99 | 62.95 | 26.26 | 43.04 | 93.71 | Upgrade
|
Revenue | 51,195 | 49,696 | 45,499 | 46,469 | 40,379 | 44,644 | Upgrade
|
Revenue Growth (YoY) | 7.81% | 9.23% | -2.09% | 15.08% | -9.56% | 15.24% | Upgrade
|
Cost of Revenue | 47,362 | 45,704 | 41,681 | 42,848 | 37,242 | 40,737 | Upgrade
|
Gross Profit | 3,833 | 3,992 | 3,817 | 3,621 | 3,136 | 3,908 | Upgrade
|
Selling, General & Admin | 1,332 | 1,430 | 1,392 | 1,355 | 1,404 | 1,473 | Upgrade
|
Research & Development | 62.17 | 71.2 | 67 | 55.75 | 51.87 | 44.93 | Upgrade
|
Other Operating Expenses | 132.53 | 109.69 | 46.91 | 120.86 | 105.54 | 104.36 | Upgrade
|
Operating Expenses | 1,532 | 1,618 | 1,498 | 1,566 | 1,571 | 1,639 | Upgrade
|
Operating Income | 2,301 | 2,374 | 2,319 | 2,055 | 1,566 | 2,269 | Upgrade
|
Interest Expense | -20.68 | -31.57 | -26.88 | -43.71 | -56.81 | -48.46 | Upgrade
|
Interest & Investment Income | 586.42 | 525.32 | 362.42 | 354.09 | 279.16 | 157.48 | Upgrade
|
Currency Exchange Gain (Loss) | 0.55 | 0.55 | -1.65 | 2.71 | 1.57 | -1.36 | Upgrade
|
Other Non Operating Income (Expenses) | 5.24 | -10.47 | -43.29 | -18 | 2.24 | -6.95 | Upgrade
|
EBT Excluding Unusual Items | 2,872 | 2,858 | 2,609 | 2,350 | 1,792 | 2,370 | Upgrade
|
Gain (Loss) on Sale of Investments | -23.91 | 10.82 | - | - | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | -0.39 | 0.08 | 1.68 | -0.07 | 0.07 | -0.53 | Upgrade
|
Other Unusual Items | 47.99 | 62.44 | 76.9 | 95.08 | 125.4 | 57.25 | Upgrade
|
Pretax Income | 2,911 | 2,931 | 2,688 | 2,445 | 1,917 | 2,427 | Upgrade
|
Income Tax Expense | 583.18 | 596.42 | 559.18 | 516.3 | 408.09 | 546.08 | Upgrade
|
Earnings From Continuing Operations | 2,327 | 2,334 | 2,129 | 1,929 | 1,509 | 1,880 | Upgrade
|
Minority Interest in Earnings | -162.51 | -188.47 | -164.65 | -174.42 | -126.56 | -276.58 | Upgrade
|
Net Income | 2,165 | 2,146 | 1,964 | 1,754 | 1,383 | 1,604 | Upgrade
|
Net Income to Common | 2,165 | 2,146 | 1,964 | 1,754 | 1,383 | 1,604 | Upgrade
|
Net Income Growth | 8.54% | 9.26% | 11.97% | 26.86% | -13.79% | 14.23% | Upgrade
|
Shares Outstanding (Basic) | 755 | 754 | 755 | 755 | 754 | 762 | Upgrade
|
Shares Outstanding (Diluted) | 755 | 754 | 755 | 755 | 754 | 762 | Upgrade
|
Shares Change (YoY) | 0.00% | -0.00% | -0.00% | 0.00% | -0.98% | -0.62% | Upgrade
|
EPS (Basic) | 2.87 | 2.84 | 2.60 | 2.32 | 1.83 | 2.10 | Upgrade
|
EPS (Diluted) | 2.87 | 2.84 | 2.60 | 2.32 | 1.83 | 2.10 | Upgrade
|
EPS Growth | 8.53% | 9.27% | 11.97% | 26.86% | -12.94% | 14.95% | Upgrade
|
Free Cash Flow | 1,540 | 2,582 | 2,265 | 1,862 | 1,233 | 1,690 | Upgrade
|
Free Cash Flow Per Share | 2.04 | 3.42 | 3.00 | 2.47 | 1.63 | 2.22 | Upgrade
|
Dividend Per Share | 0.854 | 0.854 | 0.782 | 0.700 | 0.550 | 0.638 | Upgrade
|
Dividend Growth | 9.21% | 9.21% | 11.71% | 27.27% | -13.79% | 59.50% | Upgrade
|
Gross Margin | 7.49% | 8.03% | 8.39% | 7.79% | 7.77% | 8.75% | Upgrade
|
Operating Margin | 4.49% | 4.78% | 5.10% | 4.42% | 3.88% | 5.08% | Upgrade
|
Profit Margin | 4.23% | 4.32% | 4.32% | 3.77% | 3.42% | 3.59% | Upgrade
|
Free Cash Flow Margin | 3.01% | 5.19% | 4.98% | 4.01% | 3.05% | 3.79% | Upgrade
|
EBITDA | 2,409 | 2,480 | 2,423 | 2,155 | 1,669 | 2,368 | Upgrade
|
EBITDA Margin | 4.70% | 4.99% | 5.32% | 4.64% | 4.13% | 5.30% | Upgrade
|
D&A For EBITDA | 107.88 | 106.15 | 103.86 | 100.1 | 103.46 | 98.42 | Upgrade
|
EBIT | 2,301 | 2,374 | 2,319 | 2,055 | 1,566 | 2,269 | Upgrade
|
EBIT Margin | 4.49% | 4.78% | 5.10% | 4.42% | 3.88% | 5.08% | Upgrade
|
Effective Tax Rate | 20.04% | 20.35% | 20.80% | 21.12% | 21.28% | 22.50% | Upgrade
|
Revenue as Reported | 51,195 | 49,696 | 45,499 | 46,469 | 40,379 | 44,644 | Upgrade
|
Advertising Expenses | - | 6.7 | 3.25 | 2.25 | 3.2 | 6.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.